Table 1 Ranking of barriers and facilitators, results from the pilot survey
From: Whole genome sequencing in oncology: using scenario drafting to explore future developments
Rank | Barriers | Facilitators |
|---|---|---|
1 | The clinical utility of WGS compared to TGPs will not be demonstrated sufficiently. | The clinical utility of WGS compared to TGPs has been demonstrated sufficiently. |
2 | The turnaround time of WGS will remain significantly longer compared with that of TGPs. | WGS will be included in basic health insurance. |
3 | The price of WGS will remain too high. | The price of WGS will drop significantly. |
4 | A technology that is superior in terms of cost and/or clinical utility compared to WGS will become available. | The interpretation of WGS results will become as easy as TGP results. |
5 | The interpretation of WGS results will not become easier. | The turnaround time of WGS will decrease and become equal to that of TGPs. |
6 | Fresh frozen biopsies will remain the only reliable source of DNA for WGS. | Other type of biopsies can be used for WGS, for example, liquid biopsies and FFPE biopsies. |
7 | WGS will not become part of basic health insurance. | No other technology that would compete with WGS will become available. |